Mergers & Acquisitions - Ophthalmics

Filter

Current filters:

Ophthalmics

Popular Filters

Apellis Pharma to acquire former parent Potentia

Apellis Pharma to acquire former parent Potentia

26-11-2014

USA-based Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals,…

Apellis PharmaceuticalsMergers & AcquisitionsOphthalmicsPharmaceuticalPotentia PharmaceuticalsUSA

Valeant buys NicOx’ US ophthalmic diagnostics unit

17-11-2014

Ophthalmology-focused French biotech firm NicOx says that Canada’s Valeant Pharmaceuticals International…

BiotechnologyMergers & AcquisitionsNicOxOphthalmicsUSAValeant Pharmaceuticals InternationalVesneo

MorphoSys gets milestone from Novartis; acquires new technology

21-10-2014

German company MorphoSys says it has received a milestone payment from Novartis in connection with the…

BiotechnologyLanthio PharmalanthipeptideMergers & AcquisitionsMorphoSysNovartisOphthalmicsResearch

Nicox acquires ophthalmic company Doliage and Carragelose eyedrops from Marinomed

Nicox acquires ophthalmic company Doliage and Carragelose eyedrops from Marinomed

16-09-2014

French ophthalmic company Nicox has advanced its strategy of building an international business by acquiring…

CarrageloseEuropeMarinomed BiotechnologiesMergers & AcquisitionsNicOxOphthalmicsPharmaceutical

Altacor growth to accelerate after acquisition by Esperante

Altacor growth to accelerate after acquisition by Esperante

01-08-2014

The private, Netherlands-based life science investment company Esperante says it has completed the acquisition…

AltacorDean SlagelEsperanteIn vitro diagnosticsMergers & AcquisitionsNetherlandsNicOxNYSE EuronextOphthalmicsPharmaceuticalProducerUK

Pfizer to acquire generics firm InnoPharma for up to $360 million

Pfizer to acquire generics firm InnoPharma for up to $360 million

17-07-2014

Having failed (so far) in its mega billion dollar ($116 billion) attempt to buy Anglo-Swedish drug major…

GenericsInnoPharmaMergers & AcquisitionsOncologyOphthalmicsPfizer

NicOx to acquire Aciex Therapeutics

02-07-2014

Ophthalmology-focused French biotech firm NicOx has entered into an agreement to acquire all of the outstanding…

Aciex TherapeuticsBiotechnologyInflammatory diseasesMergers & AcquisitionsNicOxOphthalmics

Merck & Co sells ophthalmic brands and Colorado biologicals unit

Merck & Co sells ophthalmic brands and Colorado biologicals unit

13-05-2014

US pharma giant Merck & Co has entered into two more divestment transactions, following the recent sell-off…

KBI BiopharmaMerck & CoMergers & AcquisitionsOphthalmicsPharmaceuticalProductionSanten Pharmaceuticals

India’s Lupin acquires Laboratorios Grin to enter Latin American market

27-03-2014

Indian pharma major Lupin has acquired a 100% equity stake in Mexican company Laboratorios Grin, subject…

IndiaLaboratorios GrinLupinMergers & AcquisitionsMexicoOphthalmicsPharmaceutical

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Akorn gains rights to Betimol from Santen

10-01-2014

US niche generic firm Akorn has acquired the New Drug Application and all rights to Betimol (timolol…

AkornBetimolMergers & AcquisitionsOphthalmicsPharmaceuticalSanten Pharmaceuticals

NicOx sets up shop in Italy with Eupharmed acquisition

26-11-2013

French biotechnology firm NicOx is planning to establish itself in Italy through a proposed acquisition…

EupharmedItalyMergers & AcquisitionsNicOxOphthalmicsPharmaceutical

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

COMPANY SPOTLIGHT

Menarini

Back to top